A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: The interim analysis data failed to demonstrate the intended treatment effect. Show 4 more changesShow less
    • Study completion date changed from estimate of Jul 2026 to Jul 13, 2026
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised at 1 of 20 sites
  2. Primary completion date: Nov 12, 2025 to Oct 18, 2025v23
  3. Trial status: Recruiting to Active, Not Recruitingv22 Show 4 more changesShow less
    • Enrollment target: estimated 200 to confirmed 63
    • Study sites: 50 to 20
    • Primary completion date changed from estimate of Aug 2027 to Nov 12, 2025
    • Study completion date: Aug 2028 to Jul 2026
  4. Site contacts updated at 13 of 50 sitesv21
  5. Site details revised at 1 of 50 sitesv20
Show 18 earlier versionsHide 18 earlier versions
  1. Site details revised at 29 of 50 sitesv19
  2. Study sites: 54 to 50v18
  3. Study sites: 50 to 54v17
  4. Site details revised at 11 of 50 sitesv16
  5. Study sites revised (50)v15
  6. Re-verified, no change to tracked fieldsv14
  7. Site details revised at 3 of 50 sitesv13
  8. Study sites: 46 to 50v12
  9. Study sites: 42 to 46v11
  10. Study sites: 41 to 42v10
  11. Study sites: 44 to 41v9
  12. Site details revised at 1 of 44 sitesv8
  13. Study sites: 43 to 44v7
  14. Study sites: 41 to 43v6
  15. Site details revised at 1 of 41 sitesv5
  16. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Apr 2025 to Aug 2027
    • Study sites: 36 to 41
    • Study completion date: Mar 2026 to Aug 2028
    • Start date changed from estimate of Mar 2024 to Mar 19, 2024
  17. Primary completion date: Aug 25, 2027 to Apr 2025
    • Study completion date: Aug 7, 2028 to Mar 2026
    • Start date: Mar 22, 2024 to Mar 2024
    v3
  18. Primary completion date: Apr 18, 2025 to Aug 25, 2027
    • Start date: Jan 25, 2024 to Mar 22, 2024
    • Study sites: 5 to 36
    • Study completion date: Mar 20, 2026 to Aug 7, 2028
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Multiple Sclerosis
1,018 trials monitored
See 34 trials at risk
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Trial Details
NCT Number NCT06220669
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Multiple Sclerosis
Related terms Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov